SEARCH

SEARCH BY CITATION

References

  • 1
    Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S122.
  • 2
    ACOG technical bulletin. Hypertension in pregnancy. Number 219–January 1996 (replaces no. 91, February 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996;53:17583.
  • 3
    Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG 2006;113:14451.
  • 4
    Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:18192.
  • 5
    Koopmans CM, Bijlenga D, Aarnoudse JG, van Beek E, Bekedam DJ, van den Berg PP, et al. Induction of labour versus expectant monitoring in women with pregnancy induced hypertension or mild preeclampsia at term: the HYPITAT trial. BMC Pregnancy Childbirth 2007;7:14.
  • 6
    Koopmans CM, Bijlenga D, Groen H, Vijgen SMC, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36’ weeks gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374:97988.
  • 7
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996. ISBN 978-0-19-510824-8.
  • 8
    Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005. ISBN 9780198529453
  • 9
    Statistics Netherlands. Statline Consumer Pricing Index, 2009. [http://www.statline.nl]. Last accessed 2 May 2008 Voorburg, the Netherlands.
  • 10
    Riteco JA, de Heij LJM, van Luijn JCF, Wolff I. Richtlijnen voor farmaco-economisch onderzoek [Guidelines for Pharmaco-economic Research]. Amstelveen: College voor Zorgverzekeringen (CvZ) [Health Insurance Board]; 1999.
  • 11
    Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20:44354.
  • 12
    Van der Kuy A. Pharmacotherapeutic Compass 2000/2001. Amstelveen: College voor zorgverzekeringen (CvZ) [Health Insurance Board]; 2000.
  • 13
    Dutch Obstetrics Consortium. 2009. [http://www.studies.obsgyn.nl]. Last accessed 15 October 2009.